Investigating the impact of programmed cell death logand-1 (PD-L1) expression in lung cancer on long-term outcome and therapeutic effect of anti-programmed cell death-1 antibody agents.

Investigating the impact of programmed cell death logand-1 (PD-L1) expression in lung cancer on long-term outcome and therapeutic effect of anti-programmed cell death-1 antibody agents. - Investigating the impact of PD-L1 expression in lung cancer on long-term outcome and therapeutic effect of anti-PD-1 antibody agents.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000025395

Enrollment

700

Registered

2016-12-24

Start date

2016-12-24

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

lung cancer

Interventions

Quantification of PD-L1 expression in histopathological specimen (by immunohistochemical analysis)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: All the patients with lung cancer undergoing surgery or receiving anti-PD-1 antibody agents between January 1st of 2006 and December 31st of 2015 EXCEPT those matching the following exclusion criteria.

Exclusion criteria

Exclusion criteria: #1 Patients with inadequate amount of their pathological sample for this study #2 Patients refusing to be enrolled in this study #3 Patients who is judged as not suitable by the administrator of this study

Design outcomes

Primary

Measure	Time frame
Protein expression of PD-L1 in lung cancer tissue	—

Secondary

Measure	Time frame
#1 Overall survival according to PD-L1 expression #2 Recurrence-free survival according to PD-L1 expression in patients undergoing complete resection for their lung cancer #3 Progression-free survival according to PD-L1 expression in patients receiving anti-PD-1 antibody agents	—

Countries

Japan

Contacts

Public ContactTomohito SAITO

Kansai Medical University Department of Thoracic Surgery

saitotom@hirakata.kmu.ac.jp072-804-0101

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026